Risk Patterns Prior to Progression From MGUS to Myeloma Call for Annual Assessments
September 20th 2019Serial assessment of blood-based immune markers showed that the risk of progression from monoclonal gammopathy of undetermined significance, the precursor disease to multiple myeloma is fluctuating rather than determinate, and these patients can experience progression to myeloma within 5 years.
Dr. D'Angelo on Bempegaldesleukin/Nivolumab Combo in Sarcomas
September 3rd 2019Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the results of a pilot study investigating the combination of bempegaldesleukin (NKTR-214) plus nivolumab (Opdivo) in patients with sarcomas.
Dr. Kris on the RELAY Trial in EGFR+ NSCLC
August 30th 2019Mark G. Kris, MD, discusses the RELAY trial, which was an international, double-blind, randomized phase III study examining erlotinib in combination with ramucirumab versus placebo in previously untreated patients with EGFR-mutant metastatic non-small cell lung cancer.
Dr. Rudin on Expansion of Immunotherapy in Lung Cancer
August 8th 2019Charles M. Rudin, MD, PhD, the Sylvia Hassenfeld Chair in Lung Cancer Research, chief, Thoracic Oncology, co-director, Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the current landscape of immunotherapy in lung cancer and how he expects the treatment to expand.
Dr. Straus on the 3-Year Results of the ECHELON-1 Study in Hodgkin Lymphoma
July 31st 2019David J. Straus, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the 3-year follow-up results of the ECHELON-1 study, which examines brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma.
Dr. Kris on Predicting Benefit With Osimertinib in EGFR+ NSCLC
June 13th 2019Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses methods for predicting benefit with osimertinib (Tagrisso) in patients with EGFR-positive non–small cell lung cancer (NSCLC).
Dr. Leitao Discusses the Role of HIPEC in Advanced Ovarian Cancer
May 7th 2019Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the role of HIPEC in patients with advanced ovarian cancer.
Dr. Slovin on Avoiding ADT-Associated Cardiac Complications in Prostate Cancer
April 17th 2019Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses ways to avoid androgen deprivation therapy (ADT)-associated cardiac complications in patients with prostate cancer.
Dr. Adusumilli on the Rationale for Mesothelin-Targeted CAR T-Cell Therapy
April 11th 2019Prasad S. Adusumilli, MD, surgeon, deputy chief of Thoracic Service, co-director of the Mesothelioma Program, head of Solid Tumors Cell Therapy, Cellular Therapeutics Center, at Memorial Sloan Kettering Cancer Center, discusses the rationale for an autologous mesothelin-targeted CAR T-cell therapy in advanced solid tumors.